01.03.2019UZH spin-off Anaveon successfully closed a CHF 35 million Series A financing

UZH spin-off Anaveon successfully closed a CHF 35 million Series A financing with the lead investor Syncona Ltd. based in the a UK. Anaveon works on a new approach for developing immunotherapies for cancer. The technology was developed by Prof. Onur Boyman. The co-founder of Anaveon is Andreas Katopodis, a former director at Novartis Institutes of Biomedical Research. The company was created in December 2017 and received its seed financing from the UZH Life Sciences Fund.

UZH Innovation Hub